Janssen has announced new clinical trial data that highlights the long-term benefits its drug Tremfya can deliver for people with plaque psoriasis.

Results from the phase III VOYAGE 2 study have shown that a vast majority of patients with moderate-to-severe plaque psoriasis receiving Tremfya maintained a strong response to continuous treatment over 72 weeks.

“Janssen has reported new clinical data showing the effectiveness of Tremfya in the treatment of moderate-to-severe plaque psoriasis.“

It was also shown that most patients originally randomised to receive Tremfya, but who were withdrawn from treatment at week 28, regained a positive response within six months of initiating retreatment.

Janssen's drug is a first-in-class approved biologic therapy that selectively blocks interleukin-23 and is administered as a 100-mg subcutaneous injection every eight weeks.

Dr Newman Yeilding, head of immunology development for Janssen, said: "To see a large majority of patients in both treatment groups achieve almost clear skin with no new safety events further supports the importance of Tremfya in the treatment of moderate to severe plaque psoriasis."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.